Dr Ajay Sharma to resign as Director - Corporate Affairs of AstraZeneca Pharma India

Written By :  Ruchika Sharma
Published On 2025-11-18 12:48 GMT   |   Update On 2025-11-18 12:48 GMT
Advertisement

Bangalore: AstraZeneca Pharma India has announced the resignation of Dr Ajay Sharma, Director - Corporate Affairs.

As per the recent BSE filing, Dr Ajay Sharma, currently serving as the Director – Corporate Affairs at the Company has decided to pursue his career outside the organization.

He will complete his handover period by close of business hours on November 26, 2025. The Company has intiated the process of identifying a suitable replacement for this position.

Advertisement

He has been associated with the company since 2020. Prior to joining AstraZeneca, he worked at the Organisation of Pharmaceutical Producers of India, Frost & Sullivan, 3M, and Home Medical Care Company.

Read also: AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia Treatment

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News